3 research outputs found
Supplementary Material for: When Do Short Children Realize They Are Short? Prepubertal Short Children’s Perception of Height during 24 Months of Catch-Up Growth Hormone Treatment
<b><i>Aim:</i></b> To examine perceived height during the first 24 months of growth hormone (GH) treatment in short prepubertal children. <b><i>Methods:</i></b> Ninety-nine 3- to 11-year-old short prepubertal children with either isolated GH deficiency (n = 32) or idiopathic short stature (n = 67) participated in a 24-month randomized trial of individualized or fixed-dose GH treatment. Children’s and parents’ responses to three perceived height measures: relative height (Silhouette Apperception Test), sense of height (VAS short/tall), and judgment of appropriate height (yes/no) were compared to measured height. <b><i>Results:</i></b> Children and parents overestimated height at start (72%, 54%) and at 24 months (52%, 30%). Short children described themselves as tall until 8.2 years (girls) and 9 years (boys). Prior to treatment, 38% of children described their height as appropriate and at 3 months, 63%. Mother’s height, parental sense of the child’s tallness and age explained more variance in children’s sense of tallness (34%) than measured height (0%). <b><i>Conclusion:</i></b> Short children and parents overestimate height; a pivotal age exists for comparative height judgments. Even a small gain in height may be enough for the child to feel an appropriate age-related height has been reached and to no longer feel short
Supplementary Material for: Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone
<b><i>Background:</i></b> The long-term safety of growth hormone treatment is uncertain. Raised risks of death and certain cancers have been reported inconsistently, based on limited data or short-term follow-up by pharmaceutical companies. <b><i>Patients and Methods:</i></b> The SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study assembled cohorts of patients treated in childhood with recombinant human growth hormone (r-hGH) in 8 European countries since the first use of this treatment in 1984 and followed them for cause-specific mortality and cancer incidence. Expected rates were obtained from national and local general population data. The cohort consisted of 24,232 patients, most commonly treated for isolated growth failure (53%), Turner syndrome (13%) and growth hormone deficiency linked to neoplasia (12%). This paper describes in detail the study design, methods and data collection and discusses the strengths, biases and weaknesses consequent on this. <b><i>Conclusion:</i></b> The SAGhE cohort is the largest and longest follow-up cohort study of growth hormone-treated patients with follow-up and analysis independent of industry. It forms a major resource for investigating cancer and mortality risks in r-hGH patients. The interpretation of SAGhE results, however, will need to take account of the methods of cohort assembly and follow-up in each country
Supplementary Material for: Growth Hormone Dose-Dependent Pubertal Growth: A Randomized Trial in Short Children with Low Growth Hormone Secretion
<b><i>Background/Aims:</i></b> Growth hormone (GH) treatment regimens do not account for the pubertal increase in endogenous GH secretion. This study assessed whether increasing the GH dose and/or frequency of administration improves pubertal height gain and adult height (AH) in children with low GH secretion during stimulation tests, i.e. idiopathic isolated GH deficiency. <b><i>Methods:</i></b> A multicenter, randomized, clinical trial (No. 88-177) followed 111 children (96 boys) at study start from onset of puberty to AH who had received GH 33 µg/kg/day for ≥1 year. They were randomized to receive 67 µg/kg/day (GH<sup>67</sup>) given as one (GH<sup>67×1</sup>; n = 35) or two daily injections (GH<sup>33×2</sup>; n = 36), or to remain on a single 33 µg/kg/day dose (GH<sup>33×1</sup>; n = 40). Growth was assessed as height<sub>SDS</sub>gain for prepubertal, pubertal and total periods, as well as AH<sub>SDS</sub> versus the population and the midparental height. <b><i>Results:</i></b> Pubertal height<sub>SDS</sub>gain was greater for patients receiving a high dose (GH<sup>67</sup>, 0.73) than a low dose (GH<sup>33×1</sup>, 0.41, p < 0.05). AH<sub>SDS</sub> was greater on GH<sup>67</sup> (GH<sup>67×1</sup>, -0.84; GH<sup>33×2</sup>, -0.83) than GH<sup>33</sup> (-1.25, p < 0.05), and height<sub>SDS</sub>gain was greater on GH<sup>67</sup> than GH<sup>33</sup> (2.04 and 1.56, respectively; p < 0.01). All groups reached their target height<sub>SDS</sub>. <b><i>Conclusion: </i></b>Pubertal height<sub>SDS</sub>gain and AH<sub>SDS</sub> were dose dependent, with greater growth being observed for the GH<sup>67</sup> than the GH<sup>33</sup> randomization group; however, there were no differences between the once- and twice-daily GH<sup>67</sup> regimens